The first non-contact, AI powered, diagnostic and therapy device
for patients suffering from obstructive sleep apnea (OSA)
Appscent Ltd. is a privately held Israeli company, developing an advanced artificial intelligence medical device that offers continuous, non-contact, diagnosis and treatment for sleep apnea.
Get in touch today to learn more about our innovative solution.
Sleep apnea is a major worldwide health problem.
Sleep apnea impacts more than 936 million people worldwide. It is a condition characterized by repetitive cessation or decreased amplitude of breathing lasting 10 seconds or more that may occur hundreds of times per night.
Apnea can result from either a central nervous system malfunction in respiratory driving (central sleep apnea, CSA) or a peripheral malfunction of upper airway collapse despite respiratory efforts (obstructive sleep apnea, OSA). CSA and OSA can materialize independently, and they can co-occur.
Sleep apnea has a significant impact on general health. Sleep apnea has been shown to contribute in the development of other conditions such as: stroke, high blood pressure, heart disease, obesity and diabetes.
Lack of Solutions
The standard and most common available treatment for sleep apnea is a highly uncomfortable and invasive device known as the CPAP (continuous positive airway pressure) which is comprised of a pump and nasal mask.
The major disadvantage of the CPAP is the relatively low compliance due to its discomfort and side effects. Roughly 12% of users abandon CPAP therapy after 1 night and only 46% use CPAP on a regular daily basis. Thus, apnea remains an often untreated disorder.
Our solution combines advanced technologies in the fields of signal processing, remote sensing, machine learning, and big data, together with the new innovative field of personalized treatment. Our device is built from two major innovative components: a diagnostic system with a learning algorithm and a therapeutic system that dispenses personalized odors, both covered by numerous patents. The innovative therapeutic system, developed by the Weizmann institute, is based on the neurological connection between the distribution of odor during sleep and the restarting of the respiratory system during apnea.
Appscent holds exclusive rights to these patents and licenses
Our disruptive innovation is a non-invasive, integrated, system that includes a diagnostic and treatment platform.
The diagnostic platform is based on remote sensing technology integrated with AI, local, and cloud based back-end. The non-contact sensors capture a range of physiological parameters which are analyzed by advanced AI algorithms that command the treatment platform to act based on a personalized physiological profile of the user.
Sleep apnea affects more than 936 million people worldwide.
The global sleep apnea device market is expected to register a CAGR of 7.6% during 5 years forecast period.
USD 9.78B by 2024 from USD 5.8B in 2018 (severe patients ~ 30% of the market).
Appscent’s market: mild & moderate apnea patients (~ 70% of the market)
The product will be sold using the razor blade model—a device sale and ongoing revenues from the sale of consumable scent capsules.
The Israel Innovation Authority, an Israeli Government body, granted Appscent a non-equity investment in order to develop the innovative technological device.
Co-Founder & CEO
13 years of experience as a Project Manager previously the manager of numerous startup accelerators. Yosi's tech background includes experience in the IDF intelligence tech units.
Co-Founder & COO
Electric Engineer with 20 years of experience. Amos is a scent based applications researcher and an odorant specialist.
Co-Founder & CTO
Senior team leader with extensive experience in application and algorithm development. David is a mentor at Google Android Academy.
Lead programer Neurosciences Researcher and Deep Learning Expert
Clinical Trials Manager
12 years of experience in the clinical research industry, a member of AICROs, and as a registered nurse in internal medicine.
Anat Arzi (Ph.D)
Post-Doctoral Fellow at the University of Cambridge, Olfactory Research Group at the Weizmann Institute
Prof. Noam Sobel
Head, Department of Neurobiology, Weizmann Institute. Prof. Sobel and his group have been routinely published in such well respected journals as Science, Nature, PNAS and Nature Neuroscience, and their work has resulted in several patents for medical devices that are now being tested in patients.
Appscent - For Free And Better Sleep
Get in touch: firstname.lastname@example.org